VISION Trial Videos

Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor

Details
Evan Yu and Oliver Sartor discuss the VISION trial's exploration of predictive and prognostic markers in the treatment of prostate cancer with Lutetium-PSMA-617. Sartor clarifies the distinction between predictive and prognostic markers, emphasizing the trial's focus on baseline markers and their association with treatment outcomes. The conversation highlights the importance of PSMA PET scans in p...

From the VISION Trial: Improved Patient Outcomes with Lutetium-PSMA-617 - Karim Fizazi

Details
In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death. Despite...

Radiographic Progression-Free Survival Correlation with Time-to-Event Endpoints in the VISION Trial - Michael Morris

Details
In this discussion, Michael Morris and Alicia Morgans discuss a post hoc analysis of the VISION Trial aimed at assessing earlier maturing time-to-event endpoints. Earlier time-to-event endpoints than overall survival (OS) will allow more timely regulatory approval and overall accelerated drug development. Morris and colleagues aimed to estimate correlations between time-to-event endpoints such as...

The Implementation of PSMA Theranostics in Clinical Practice - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans in a discussion on the implementation of PSMA theranostics and treating patients with lutetium in clinical practices. Drs Morgans and Sartor talk through the logistics of this integration, patient selection, and treatment choice for prolonging survival and improving quality of life. Dr. Sartor also highlights potential novel expanded indications that we may see i...

Integrating 177Lu-PSMA-617 in Clinical Practice - Oliver Sartor

Details
Oliver Sartor and Alicia Morgans delve into the complexities of implementing Lutetium-177 in clinical practices, especially amid recent supply chain issues. Dr. Sartor emphasizes the importance of multidisciplinary care and effective communication between medical oncologists and radiation oncologists for successful patient management. He outlines the licensure requirements and safety protocols nec...

A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore

Details
Urologist Neal Shore joins Alicia Morgans in a discussion on the integration of lutetium into clinical practices. Dr. Shore reviews the phase 3 VISION trial which led to the approval of Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. They discuss steps to thoughtfully and practically, integrate this new therapeutic into our treatment paradigm. Biographies: Neal Shore, MD...

Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC - Oliver Sartor

Details
Oliver Sartor joins Phillip Koo to discuss the United State FDA approval of Pluvicto™ (177Lu-PSMA-617) as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). They discuss currently enrolling in clinical trials with Pluvicto in the pre-chemotherapy treated mCRPC patient population. They look further into the future discu...

Pluvicto The First Targeted Radioligand Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer FDA Approved - Charles Ryan and Alicia Morgans

Details
Drs Charles Ryan and Alicia Morgans discuss the approval of Pluvicto TM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617). Pluvicto was approved based on the pivotal Phase III VISION trial which evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined...

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer, The VISION Trial Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen highlight the New England Journal of Medicine VISION trial publication entitled, "Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer." In the VISION trial, radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive me...

Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor

Details
Alicia Morgans and Oliver Sartor discuss additional data from the VISION trial that was recently presented at ESMO 2021. Dr. Sartor discusses the health-related quality of life findings from the VISON specifically pain and symptomatic skeletal events. Dr. Sartor offers the background on the VISION trial, while also describing the patient cohorts. Dr. Sartor discusses how the trial patients randomi...